Histogen — IPO Roadshow (December 2020)
22 slides from Histogen's IPO roadshow presentation, Dec 29, 2020
Slide 1: Restoring Function Enhancing Lives
Restoring Function Enhancing Lives December 2020 Issuer Free Writing Prospectus dated December 29, 2020 Filed pursuant to Rule 433 under the Securities Act of 1933 Relating to the Preliminary Prospectus dated December 29, 2020 Registration Statement No. 333-251491
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are intended to be covered by the safe harbor provisions of the Privat
Slide 3: Developing potential first-in class restorative therapeutics
Developing potential first-in class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function Proprietary hypoxia-generated growth factor technology platform Comprehensive IP portfolio with 52 global issued and pending patents Pipeline focused
Slide 4: Proprietary Technology Platform Yields Multiple Product Candidate Opportunities
Proprietary Technology Platform Yields Multiple Product Candidate Opportunities Growing fibroblast cells under simulated embryonic conditions to induce them to become multipotent cells that generate biological materials, growth factors and proteins, which have the potential to stimulate a patient’s
Slide 5: Robust Pipeline and Partnerships
Robust Pipeline and Partnerships Preclinical Phase 1 Phase 2 Phase 3 Marketed/Partner CCM Cosmetics HST 001 Hair Growth (HSC) HST 002 Dermal Filler (hECM + Lidocaine) HST 003 Joint Cartilage (hECM) HST 004 Spine (CCM) BLA BLA NDA World Wide Rights China Emricasan COVID-19 (Pan-Caspase Inhibitor) BLA
Slide 6: Clinical Programs
Hilogen Clinical Programs
Slide 7: HST Hair Growth Overview
HST 001 Hair Growth Overview If approved, HST 001, would be the only product to grow new terminal and vellus hairs; Current approved products preserve existing hair to reduce overall hair loss Human proteins and growth factors stimulate resting hair follicles to produce new cosmetically-relevant hai
Slide 8: HST 001 Hair Growth Clinical Proof-of-Concept
Three Completed Company-Sponsored Clinical Trials Pilot in male pattern hair loss Phase 1a in male pattern hair loss Phase 1a in female diffuse hair loss Strong Safety Profile No kidney, liver or bone marrow toxicity No severe adverse events Treatment well tolerated across all subjects Statistically
Slide 9: HST 001 Hair Growth Phase 1b/2a Protocol
Objective: Optimal dosing of HSC in male pattern hair loss Enrollment Criteria: 36 men, aged 20-55 Male pattern hair loss (Norwood-Hamilton 3V, 4, 5) Treatment Regimen: 20 injections of HSC week 0, week 6, week 12 20 injections of placebo (PBS) week 0, week 6, week 12 Endpoints: Adverse events and s
Slide 10: HST 001 Phase 1b/2a Trial Week 18 Preliminary Results
At the week 18 primary efficacy endpoint assessment of change from baseline in total hairs (terminal and vellus) in the target area (TAHC) in the vertex as measured by Canfield’s Hairmetrix macrophotography system HST-001 did not achieve statistical significance HST-001 did demonstrate separation fr
Slide 11: HST Joint Cartilage Overview
HST 003 Joint Cartilage Overview If approved, HST 003, would be the only product that regenerates hyaline cartilage which could potentially improve functionality, mobility, and provide reduction in inflammation and pain Malleable scaffold applied to full-thickness chondral lesions as part of an arth
Slide 12: HST Joint Cartilage Preclinical Proof-of-Concept
HST 003 Joint Cartilage Preclinical Proof-of-Concept Rat model Untreated defects (10) - extensive fibrotic tissue and no articular cartilage at 6 weeks Treated defects (10) - congruent and smooth cartilage regeneration and integration with surrounding cartilage at 6 weeks (O’Driscoll p<0.001) Rabbit
Slide 13: HST Joint Cartilage Phase 1/2 Protocol
HST 003 Joint Cartilage Phase 1/2 Protocol Objective: Evaluate the safety of hECM paste delivered arthroscopically during microfracture procedure Enrollment Criteria: 15 patients who are candidates for microfracture surgery Recent focal cartilage defects of 2 - 4cm2 in the knee 3 sites: Walter Reed
Slide 14: Emricasan – Targeting COVID-19 Overview
Emricasan is a first-in-class, orally active, pan-caspase inhibitor designed to reduce the activity of enzymes that mediate inflammation and apoptosis (programmed cell death) Histogen and Amerimmune Development and Collaboration Agreement Histogen retains ownership and oversight over emricasan and r
Slide 15: Emricasan – Pre-Clinical and Clinical Proof-of-Concept
Mechanism of Action Emricasan is a pan-caspase inhibitor that irreversibly inactivates caspases Exhibited good target specificity across many caspases, such as caspase-1, caspase-3, caspase-7, all caspases involved in inflammation signaling (e.g. caspase-1) and apoptosis initiation and progression (
Slide 16: Caspases Cover Entire COVID-19 Disease Spectrum
Caspase-1 activation leads to T cell loss in other viral infections (e.g. MERS, SARS, HIV) Caspase-1 activation leads to T cell loss in other viral infections (e.g. MERS, SARS, HIV) In vitro, emricasan reduces caspase-1 activity in T-helper cells and red blood cells isolated from COVID-19 patients E
Slide 17: Emricasan - Targeting COVID-19 Phase 1 Protocol
Objective: Primary safety and tolerability in symptomatic, outpatient, mild-COVID-19 patients and assessment of prevention of disease progression Enrollment Criteria: 40 symptomatic, outpatient, mild-COVID-19 patients Randomization: 1:1 (active: placebo) Treatment Regimen: Emricasan at 25 mg BID dos
Slide 18: Summary and Leadership
Summary and Leadership
Slide 19: Key Near-Term Clinical Development Milestones
2021 2020 2022 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 HST 001 HST 003 CNATEMRaaa HST 004 Key Near-Term Clinical Development Milestones Submit IND Final Week 26 Results Initiate P1 Study Initiate P1 Study P1 Results Top-line Results
Slide 20: Accomplished Leadership Team
Accomplished Leadership Team Gail Naughton, Ph.D. Founder/Chief Scientific Officer Martin Latterich, Ph.D. Sr. VP of Technical Operations Richard Pascoe President and CEO Susan Knudson Chief Financial Officer Moya Daniels, M.S. Head of Regulatory Affairs, Quality & Clinical Operations
Slide 21: Positioned for Growth
Positioned for Growth Validated Technology Demonstrated pre-clinical/clinical proof of concept with HSC and hECM CCM marketed by Allergan in their SkinMedica TNS A+ brand Strategic Pipeline Targeting high-value markets with potential first-in-class product candidates Clinical development programs de
Slide 22: Restoring Function Enhancing Lives
Restoring Function Enhancing Lives December 2020